Tag:
Bydureon
Latest Headlines
Latest Headlines
Bristol stays in hunt for Amylin
After Amylin reportedly declined BMS' recent buyout offer, Bristol isn't giving up on its plans to gobble up the diabetes drugmaker, The Wall Street Journal reported.
AstraZeneca scouts new drug deals to silence a chorus of critics
The instant the news hit that Amylin had rebuffed a $3.5 billion buyout offer from Bristol-Myers Squibb, analysts began to speculate that AstraZeneca might like to step in.
Is an Amylin takeover inevitable after the BMS rejection?
Now that Amylin has rejected a $3.5 billion offer from Bristol-Myers, what is its next step?
UPDATED: Amylin shares rocket up on report of $3.5B buyout offer by Bristol-Myers
Shares of Amylin Pharmaceuticals ( $AMLN ) rocketed up more than 40% this morning, fueled by a report that the Bydureon developer had turned down a $22 per share buyout offer from Bristol-Myers Squibb ( $BMY ).
Amylin's OH plant prepped for Bydureon's U.S. debut
In anticipation of the U.S. approval of Bydureon, San Diego's Amylin Pharmaceuticals ( $AMLN ) was already amping up production of the diabetes drug at its West Chester Township, OH, plant where...
Amylin gets FDA OK for weekly diabetes drug Bydureon
Say hello to Bydureon , a once-weekly injectable treatment for Type 2 diabetes finally approved by the FDA on Jan. 27. Amylin Pharmaceuticals ( $AMLN ) developed the drug using controlled release drug
FDA nod fuels Bydureon vs. Victoza bout
Amylin Pharmaceuticals' ( $AMLN ) projected blockbuster Bydureon has won FDA approval, adding muscle to the San Diego-based drug company's counterpunch against rival Novo Nordisk ( $NVO ) in the big
UPDATED: FDA (finally) stamps an approval on Amylin's Bydureon
After being rejected twice by regulatory officials, Amylin has finally won FDA approval to sell Bydureon, its once-weekly diabetes jab. The news sent Amylin's shares up 16% while Alkermes ($ALKS),
It's final: Tasigna in, Sprycel out in NICE guidelines
The National Institute for Health and Clinical Excellence has struck again. Despite two appeals of its draft recommendations, the agency let in only one new drug for chronic myeloid leukemia.
Alkermes keeps drug-delivery ties intact in Lilly-Amylin breakup
Alkermes ( $ALKS ) has come through the divorce between its partners Amylin ( $AMLN ) and Eli Lilly ( $LLY ) unscathed, with all of its royalty rights to sales of extended-release exenatide or Bydureon ,...
